Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 studyLancet Oncol 2022 Apr 27;[EPub Ahead of Print], R Motzer, C Porta, B Alekseev, SY Rha, TK Choueiri, MJ Mendez-Vidal, SH Hong, A Kapoor, JC Goh, M Eto, L Bennett, J Wang, JJ Pan, TL Saretsky, RF Perini, CS He, K Mody, D Cella
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.